Research programme: PTEN modulators - Semafore Pharmaceuticals

Drug Profile

Research programme: PTEN modulators - Semafore Pharmaceuticals

Alternative Names: PTEN inhibitors research programme - Semafore

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Semafore Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Chemotherapy-induced damage; Radiation injuries

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Chemotherapy induced damage (Prevention) in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Radiation injuries (Prevention) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top